Consort Medical (CSRT)
market vs.
industry GROWTH & VALUE
| 12m Forecast Rolling | ||||
| PE Ratio (f) | 17.5 |
|
|
|
| PEG Ratio (f) |
|
|
||
| EPS Growth (f) | % |
|
|
|
| Dividend Yield (f) | % |
|
|
|
| Valuation (ttm) | ||||
| Price to Book Value | 2.40 |
|
|
|
| Price to Tang. Book |
|
|
||
| Price to Free Cashflow |
|
|
||
| Price to Sales |
|
|
||
| EV to EBITDA |
|
|
||
market vs.
industry QUALITY
| Year End 30th Apr | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | TTM | 2013E | 2014E | CAGR / Avg | |
| Revenue | £m | ||||||||||
| Operating Profit | £m | ||||||||||
| Net Profit | £m | ||||||||||
| EPS Reported | p | ||||||||||
| EPS Normalised | p | ||||||||||
| EPS Growth | % | ||||||||||
| PE Ratio | x | ||||||||||
| PEG | x | ||||||||||
| Profitability | |||||||||||
| Operating Margin | % | ||||||||||
| ROA | % | ||||||||||
| ROCE | % | ||||||||||
| ROE | % | ||||||||||
| Cashflow | |||||||||||
| Op. Cashflow ps | p | ||||||||||
| Capex ps | p | ||||||||||
| Free Cashflow ps | p | ||||||||||
| Last ex-div: 16th Jan, paid: 15th Feb more... Dividends | |||||||||||
| Dividend ps | p | ||||||||||
| Dividend Growth | % | ||||||||||
| Dividend Yield | % | ||||||||||
| Dividend Cover | x | ||||||||||
| Balance Sheet | |||||||||||
| Cash etc | £m | ||||||||||
| Working Capital | £m | ||||||||||
| Net Fixed Assets | £m | ||||||||||
| Net Debt | £m | ||||||||||
| Book Value | £m | ||||||||||
| Average Shares | m | ||||||||||
| Book Value ps | p | +4.4% | |||||||||
FINANCIAL BRIEF: For the six months ended 31 October 2012, Consort Medical plc revenues increased 2% to L72.2M. Net income decreased 20% to L7M. Revenues reflect Kings System Division segment increase of 4% to L22M, Bespak division segment increase of less than 1% to L50.4M, Europe segment increase of 19% to L29.1M, Rest of the World segment increase of 6% to L8.6M. Net income was offset by Unallocated segment loss totaling L1.6M vs. income of more »
| Leverage (ttm) | Total | Ex Intang | |||
| Gross Gearing | % | ||||
| Net Gearing | % | ||||
| Cash / Assets | % | ||||
| Liquidity (ttm) | ||
| Current Ratio | ||
| Quick Ratio | ||
| Interest Cover | ||
| Efficiency (ttm) | ||
| Asset Turnover | ||
| Rec's Turnover | ||
| Stock Turnover | ||
market vs.
industry RECENT HISTORY
| Latest interim period (ended 31st Oct '12) vs. prior year | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| 3yr Average Annualised | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| DPS Growth | % |
|
|
|
BROKER CONSENSUS & FORECAST TREND
| Recommendation: | Strong Sell | Sell | Hold | Buy | Strong Buy |
|---|---|---|---|---|---|
| No. of Analysts: | 1 | 0 | 2 | 1 | 5 |
Consort Medical plc is a healthcare company focused on medical technologies. The principal activities of the Company are the design, development and manufacture of specialty medical drug delivery devices and services to the pharmaceutical industry through its Bespak Division and disposable airway management products for critical care settings in hospitals and pre-hospital settings through its King Systems Division. The Company’s products include metered dose inhalers, dry powder devices, actuators, compliance aids, disposable autoinjectors, needlefree reusable jet injectors, disposable facemasks, breathing circuits, laryngeal tubes and video laryngoscopes. The Company operates through two divisions: Bespak which consists of respiratory and an injectables business; and King Systems, a United States-based anaesthesia products business. In February 2013, it announced the disposal of its King Systems division (King).
Directors: Jonathan Glenn (CEO) 43, Richard Cotton (Fin. Dir.) , John Slater (Counsel) , Nick Higgins (Exec. Dir.) 55,
No. of Employees: 1,163 No. of Shareholders: n/a
| Last Annual | April 30th, 2012 |
| Last Interim | October 31st, 2012 |
| Shares in Issue | 29,198,124 |
| Free Float | 26.6m (91.1%) |
| Sector | Healthcare |
| Industry | Healthcare Equipment & Supplies |
| Index | FTSE Small Cap , FTSE Small Cap XIT, FTSE Techmark Focus , FTSE Techmark All-share, |
| Exchange |
London Stock Exchange (Full) |
| Eligible for | an ISA? a SIPP? |
| Address | Ground floor Suite D,Breakspear Park Breakspear Way, HEMEL HEMPSTEAD, HP2 4TZ, United Kingdom |
| Web | http://www.consortmedical.com |
| Phone | +44 1442 867920 |
| Contact | Jenny Owen (Secy.) |
| Registrar | Capita Registrars (Kent) |
| Auditors | PricewaterhouseCoopers LLP |
| 3rd May | King Vision Deferred Consideration Update |
| 30th Apr | Holding(s) in Company |
| 25th Apr | Holding(s) in Company |
| 24th Apr | Director/PDMR Shareholding |
| 15th Apr | Blocklisting Interim Review |
| 8th Apr | Holding(s) in Company |
Recent ↓
